REMARKS

By this Office Action, the Examiner has required restriction to one of the following inventions:

I. Claims 20-26, drawn to ONE isolated nucleic acid, a vector thereof, and cultured cell, classified in class 536, subclass 23.1; class 435, subclasses 69.1, 320.1, 325.


(Upon electrion of Group I above, Applicant must further elect ONE nucleic acid from those listed in Calim 20, part a, and ONE corresponding encloded polypeptide from those listed in Claim 21, part a, as each sequence represents a separate invention, not a species. Additionally, Claim 26 will only be examined to the extent it reads on the elected sequence(s).)

II. Claims 14-19, 27, 30-33 drawn to ONE purified polypeptide, classified in class 530, subclass 350; class 424, subclass 184.1.

(Upon election of Group II above, Applicant must further elect ONE polypeptide sequence from those listed in Claim 27, part a, as each sequence represents a separate invention, not a species. Claims 14-19 will only be examined to the extent they read on the elected sequence.)

III. Claims 1-12, drawn to ONE CA125 molecule comprising an extracellular domain of SEQ ID NO.: 299, ONE repeat domain, and ONE cytoplasmic domain comprising SEQ ID NO.: 300, classified in class 530, subclass 350.

(Upon election of Group III, Applicant must further elect ONE multiple repeat domain corresponding to ONE linear sequence identifier comprising smino acids 1-156 of domains 1-5. For example, upon election, of Group III, a search and examination of a 2077 AA polypeptide will take place as set forth below:



- IV. Claim 13, drawn to a CA125 molecule comprising SEQ ID NO.: 162, classified in class 530, subclass 350.
- V. Claims 28-29 drawn to a purified antibody that binds to ONE polypeptide, classified in class 530, subclass 387.1.

(Upon election of Group V above, Applicant must further elect ONE polypeptide sequence from those listed in Claim 28, part a, as each sequence represents a separate invention, not a species.)

VI. Claim 34, drawn to ONE antisense molecule, classified in class 800, subclass 286.

(Upon election of Group VI above, Applicant must further elect ONE nucleic acid from those listed in Claim 20, part a, as each sequence represents a separate invention, not a species.)

Responsive to the Requirement for restriction, Applicant elects to prosecute the invention of group III, with traverse Claims 1-12 drawn to one polypeptide. The applicant elects the repeat domain as shown in SEQ ID NO. 150 for examination.

Applicants respectfully request reconsideration of the Requirement for Restriction, or in the alternative, modification of the Restriction Requirement to allow prosecution of more than one group of Claims designated by the Examiner in the present Application, for the reasons provided as follows.

Under 35 U.S.C § 121 "two or more independent and distinct inventions . . . in one Application may . . . be restricted to one of the inventions." Inventions are "independent" if "there is no disclosed relationship between the two or more subjects disclosed" (MPEP 802.01).

The term "distinct" means that "two or more subjects as disclosed are related . . . but are capable of separate manufacture, use or sale as claimed, AND ARE PATENTABLE OVER EACH OTHER" (MPEP 802.01) (emphasis in original). However, even with patentably distinct inventions, restriction is not required unless one of the following reasons appear (MPEP 808.02):

- 1. Separate classification
- 2. Separate status in the art; or
- 3. Different field of search.

Further, under patent Office Examining Procedures, "[i]f the Search and Examination of an entire Application can be made without serious burden, the Examiner <u>must</u> examine it on the merits, even though it includes claims to distinct or independent inventions" (MPEP 803, Rev. 8, May 1988) (emphasis added).

The Examiner's assertions to the contrary notwithstanding, Applicants respectfully submit that conjoint examination and inclusion of all of the Clams of the present Application would not present an undue burden on the Examiner, and accordingly, withdrawal of the Requirement for Restriction.

With respect to the requirement to elect a single species for examination on the merits, Applicants respectfully traverse this requirement for the following reasons:

I. Claim 1(b) providing the multiple repeat domains does not include a genus species relationship

Claim 1(b) relates to a <u>multiple</u> repeat domain. A CA125 molecule can include a variety, if not <u>all</u> of the repeats in a single molecule. SEQ ID NO: 162 which show the recombinant molecule has been marked up as Appendix Tab A, to show the <u>multiple</u> repeats present in a single molecule. Claims to be restricted to different species must be mutually exclusive. The general test as to when claims are restricted respectively to different species is the fact that one claim recites limitations which under the disclosure are found in a first species, but not in a second, while a second claim recites limitations disclosed only from the second species and not the first. MPEP § 12.0[3[c]. As can be seen from an inspection of the recombinant molecule shown in SEQ ID NO: 162, CA125 molecule within the scope of claim 1(b) may have multiple

repeat domains which are not mutually exclusive. Consequently, Applicants respectfully request examination on the multiple repeat domains as claimed. This requirement to elect a single combination of repeats violates the basic right of the Applicants to claim his invention as he chooses. <u>In re Weber</u>, 580 F.2d 455 (USCC 1978).

II. Restriction is not appropriate if the claims are directed to substantially the same molecule

Species are patentably distinct when they are related, but they are capable of separate manufacture and are patentable (novel and nonobvious) over each other. The multiple repeat domains contain multiple repeats wherein each repeat unit has five genomic exons. The variation in repeats set out in Claim 1 (b) are 82% identical and thus present related chemical compounds. The repeat domain is a sequence of 156 amino acids which are repeated multiple times within a discrete portion of the CA125 protein. The repeat domain has its own function and combines with the other domains to provide the overall function of the protein. The designated exons in the repeat domain can vary, but, this variance is minimal. Importantly, when the nucleic acids are expressed they form a CA125 protein. Restriction is not appropriate if claims are directed to the same protein.

In view of the above, withdrawal of the Requirement for the Restriction is requested, and an early action on the merits of the Claims is courteously solicited.

Respectfully Submitted,

BUTLER, SNOW, O'MARA, STEVENS & CANNADA

Date:

Bv:

Susan B. Fentress

Registration No. 31,327

6075 Poplar Avenue, Suite 500

Memphis, TN 38187

Telephone: 901-680-7319

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being	deposited with the United States Postal Service as first
class mail, postage prepaid, on 10/5/2005	, in a package addressed to: Mail Stop: AMENDMENT A 22313-1450.
Commissioner for Patents, P.O. Box 1450, Alexandria, V.	A 22313-1450.
•	

MEMPHIS 171783v1

multiple report domain

A ŢVPFMV	PFTL NFTITNI	LQYE EDMRHPG	SRK		
12101	FNATERELQ	JLKPLFRNSS	LEYLYSGCRL	ASLIPEKOSS	AMAVDAICTH
12151	RPDPEDLGLI	RERLYWELSN	LTNGIQELGP	YTLDRNSLYV	NGFTHRSSMP
12201	TISTEGIST	DVGTSGTPSS	SPSPTA	sinuida investa	innungayaying j
12251	A FIRM COMP				
12301	\$7.50 JUNE 10.24		avita č ki (Brive	างสร้างสุด	SUNPERIOR OF CHIEF
1235		el el calicavio popolo e	SERRESER	JI MAGPLLV	PFTLNFTITN
12401	LOYGEDMGHE	GSRKFNTTER	vlogitgeif	KNTSVGPLYS	GCRLTSLRSE
12451	KDGAATGVDA	Z34 ICIHHLDPKS	PGLNRERLYW	ELSQLTNGIK	ELGPYTLDRN
12501	SLYVNGFTHE	TSVPTSSTPG	TSTVDLGTSG	TPFSLPSPAT	ACREVETL
12551	Name of States	izoviistyespito	IEN PREDRIVERON	Tressiekon?	VE EVSGCRI
12601	PER PEROPE	Projevjetovalenia	RULED DICE PER D	REGLANDISO	Anng kengha
12651	STRUDENCE W	enie projekte	resemble reserv	preservesi.	PERMAGPLL
12701	VPFTLNFTIT	**		RVLQGIILGPM	
12751	SGCRLTLLR	EKDGAATGVD	AICTHRLDPK	SPGVDREQLY	WELSQLTNGI
12801	KELGPYTLDR	NSLYVNGFTH	QTSAPNTSTP	GTSTVDLGTS	GTPSSLPSPT
12851		ENCLIEBLOX	EEDMRHPESR	RENTTERVACO	(GALKPIAPKS#
12901	THX Experiences	TELEVIPETIONS	A CHEVE ASSETS	directors received	DREET XWELL
12951	A PER	Eveljeansly	Vol important	entistieten sp	VDEGREER'S
13001		LLVPFTLNFT	ITNLQYEEDM	HHPGSRKFNT	TERVLQGILG
13051	PMFKNTSVGL	LYSGCRLTLL	PEKNGAATG		PKSPGLNREQ
13101	_	GIKELGPYTL	DRNSLYVNG	THRSSVAPTS	TEGTSTVDLG
13151	728-3 TSGTPSSLPS	PTITATORNA	TERRIT TERRIT	erseletimiki (Pre	SEAFNERV.
13201	14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		GENERAL GENERAL	NATURAL DAME	OTHENBOOP X
13251	e in company of	au Soldierie (S. 15)	CONTROL OF THE		Secretary 1
13301		PSEVESETTA	GPLLVPFTLN	FTITNLQYEE	DMHRPGSRKF
13351	natervlogl	LSPIFKNSSV	GPLYSGCRLT	SLRPEKDGAA	TGMDAVCLYH
13401	PNPKRPGLDR	EQLYWELSQL	THNITELGPY	SLDRDSLYVN	GETHONS VPT
13451	TSTPGTSTVY	Z 80 WATTGTPSSF	PGHTEPGPLL	I XQ IPFTFNETIT	NLHYEENMQH

200 PGSRKFNTTE RVLQGLLKPL FKNTSVGPLY SGCRLTSLAP EKDGAATGMD 13501 AVCLYHPNPK RPGLDREQLY CELSQLTHNI TELGPYSLDR DSLYVNGFTH 13551 QNSVPTTSTP GTSTVYWATT GTPSSFPGHT EPGPLLIPFT FNFTITNLHY 13601 EENMOHPGSR KFNTTERVLQ GILKPLFKNT SVGPLYSGCR LTLLRPEKHE AATGVDTICT HRVDPIGPGL DRERLYWELS QLTNSITELG PYTLDRDSLY 13701 271 787 VNGFNPRSSV PTTSTPGTST-VHLATSGTPS-SLPGRIAPVP-ILLITETLNET ITNLHYEENM QHPGSKKFRT TERVLOGILR PLFKNTSVGP LYSGCRLTLL 13801 13851 RPEKHEAATG VDTICTHRVD PIGPGLDREX LYWELSXLTX XIXELGPYXL DRXSLYVNG XXXXXXXXX TPGTSXVXLX TSGTPXXXPX XTSAGPLLVP 13901 FTLNFTITHL QYEEDMHPG SRKFNTTERV LQGILGPMFK NTSVGLLYSG 13951 CRLTLLEGER MGHATGMUAT CEMRLIDERS GLIDREGLEWE LEGITHO LGPYTLDRNS LYVNGETHRS SVAPTSTPGT STVDLGTSGT PSSLPSPTTA VPLLVPFTLN FTITNLQYGE DMRHPGSRKF NTTERVLQGL LGPLFKNSSV 14101 205
GPLYSGCRLI SLRSEKDGAA TGVDAICTHH LNPQSPGLDR EQLYWQLSQM 14151 TIGIKELGPY TLDRINSLYVN GETHRSSGLT TSTPWTSTVD LGTSGTPSPV 14201 PSPTTAGPLL VPFTLNFTIT NLQYEEDMHR PGSRKFNATE RVLQGLLSPI 14251 FKNSSVGPLY SGCRLTSLRP EKDGAATGMD AVCLYHPNPK RPGLDREQLY 14301 WELSQLTHNI TELGPYSLDR DSLYVNGFTH QSSMTTTRTP DTSTMHLATS RTPASLSGPT TASPLLVLFT INCTITULQY EEDMRRTGSR KFNTMESVLQ GILKPLFKNT SVGPLYSGCR LTLLRPKKDG AATGVDAICT HRLDPKSPGL NREQLYWELS KLINDIEELG PYTLDRNSLY VNGFTHOSSV STISTPGTST VDLRTSGTPS SLSSPTIMXX XPLLXPFTLN FTITNLXYEE XMXXPGSRKF NTTERVLOGL LRPLFKNTSV SSLYSGCRLT LLRPEKDGAA TRVDAACTYR 14601 PDPKSPGLDR EQLYWELSQL THSTTELGPYT THINKYSTYVN TENPKSSVP 14651 TSTPGTSTVH LATSGTPSSL PGHTXXXPLL XPFTLNFTIT NLXYEEXMXX 14701 14751 PGSRKFNTTE RVLQGLLKPL FRNSSLEYLY SGCRLASLRP EKDSSAMAVD AICTHRPDPE DLGLDRERLY WELSNLTNGI QELGPYTLDR NSLYVNGFTH 259
RESFLITSTP WISTVOLGTS GTPSPVPSPT TAGPLLVPFT LNFTITNLQY

RPEKRGAATG VDTICTHRLD PLNPGLDREX LYWELSXLTX XIXELGPYXL DRXSLYVNGF XXXXXXXXTS TPGTSXVXLX TSGTPXXXPX XTXXXPLLXP 17801 FTLNFTITNL XYEEXMXXPG SRKFNTTERV LQGILXPXFK XTSVGXLYSG 17851 CRLTLLEXEK XXAATXVDXX CXXXXDPXXP GLDREXLYWE LSXLTXXIXE 17901 LGPYXLDRXS LYVNCFHPRS SVPTTSTPGT STVHLATSGT PSSLPGHTAP 17951 VPLLIPFTLN FTITNLHYEE NMQHPGSRKF NTTERVLQGL LGPMFKNTSV 18001 GLLYSGCRLT LLEPEKNGAA TGMDAICSHR LDPKSPGLDR EXLYWELSXL 18051 TXXIXELGPY XLDRXSLYVN GEXXXXXXXX TSTPGTSXVX LXTSGTPXXX 18101 PXXTXXXPLL XPFTLNFTIT NLXYEEXMXX PGSRKFNTTE RVLQGQLXPX 18151 FKXTSVGXLY SGCRLTLLRK EKXXAATXVD XXCXXXXDPX XPGLDREXLY 18201 WELSXLTXXI XELGPYXLDR XSLYVNCFTH QNSVPTTSTP GTSTVYWATT 18251 GTPSSFPGHT EPGPLLIPFT FNFTITNLHY EENMQHPGSR KFNTTERVLQ 18301 GILTPLFKNT SVGPLYSGCR LTLLRPEKQE AATGVDTICT HRVDPIGPGL 18351 DREXLYWELS XLTXXIXELG PYXLDRXSLY VNGFXXXXXX XXTSTPGTSX 18401 VXLXTSGTPX XXPXXTXXXP LLXPFTLNFT ITNLXYEEXM XXPGSRKFNT 18451 TERVLOGILX PXFKXTSVGX LYSGCRLTLL RXEKXXAATX VDXXCXXXXD 18501 PXXPGLDREX LYWELSXLTX XIXELGPYXL DRXSLYVNGF THRSSVPTTS 18551 SPGTSTVHLA TSGTPSSLPG HTAPVPLLIP FTLNFTITNL HYEENMOHPG 18601 SRKFNTTERV LOGICKPLFK STSVGPLYSG CRLTLLEPEK HGAATGVDAI 18651 18701 CTLRLDPTGP GLDREXLYWE LSXLTXXIXE LGPYXLDRXS LYVNGFXXXX XXXXTSTPGT SXVXLXTSGT PXXXPXXTXX XPLLXPFTLN FTITNLXYEE 18751 XMXXPGSRKF NTTERVLQGL LXPXFKXTSV GXLYSGCRLT LLRKEKXXAA 18801 TXVDXXCXXX XDPXXPGLDR EXLYWELSXL TXXIXELGPY XLDRXSLYVN 18851 GETHRTSVPT TSTPGTSTVH LATSGTPSSL PGHTAPVPLL IPFTLNFTIT 18901 NLOYEEDMHR PGSRKFNTTE RVLOGILSPI FKNSSVGPLY SGCRLTSLRP 18951 EKDGAATGMD AVCLYHPNPK RPGLDREQLY CELSQLTHNI TELGPYSLDR 19001 DSLYVNGFTH QNSVPTTSTP GTSTVYWATT GTPSSFPGHT XXXPLLXPFT 19051 19101 LNFTITNLXY EEXMXXPGSR KFNTTERVLQ GILXPXFKXT SVGXLYSGCR LTLLEXEKXX AATXVDXXCX XXXDPXXPGL DREXLYWELS XLTXXIXELG 19151

19201 PYXLDRXSLY VNGFTHWSSG LTTSTPWTST VDLGTSGTPS PVPSPTTAGP 19251 LLVPFTLNFT ITNLQYEEDM HRPGSRKFNA TERVLQGULS PIFKNTSVGP 19301 LYSGCRLTLL RPEKQEAATG VDTICTHRVD PIGPGLDREX LYWELSXLTX 19351 XIXELGPYXL DRXSLYVNGF XXXXXXXXTS TPGTSXVXLX TSGTPXXXPX XTXXXPLLXP FTLNFTITNL XYEEXMXXPG SRKFNTTERV LQGILXPXFK XTSVGXLYSG CRLTLLEKEK XXAATXVDXX CXXXXDPXXP GLDREXLYWE LSXLTXXIXE LGPYXLDRXS LYVNOFTHRS FGLTTSTPWT STVDLGTSGT PSPVPSPTTA GPLLVPFTLN FTITNLQYEE DMHRPGSRKF NTTERVLQGL LTPLFRNTSV SSLYSGCRLT LLEPEKDGAA TRVDAVCTHR PDPKSPGLDR EXLYWELSXL TXXIXELGPY XLDRXSLYVN QFXXXXXXXX TSTPGTSXVX 19651 LXTSGTPXXX PXXTXXXPLL XPFTLNFTIT NLXYEEXMXX PGSRKFNTTE 19701 RVLOGILXPX FKXTSVGXLY SGCRLTLLEK EKXXAATXVD XXCXXXXDPX XPGLDREXLY WELSXLTXXI XELGPYXLDR XSLYVNGTH WIPVPTSSTP 19801 GTSTVDLGSG TPSSLPSPT AGPLLVPFTL NFTITNLQYG EDMGHPGSRK FNTTERVLOG ILGPIFKNTS VGPLYSGCRL TSLRSEKDGA ATGVDAICH HLDPKSPGLD REXLYWELSX LTXXIXELGP YXLDRXSLYV NGFXXXXXXX XTSTPGTSXV XLXTSGTPXX XPXXXXXPL LXPFTLNFTI TNLXYEEXMX XPGSRKFNTT ERVLOGILXP XFKXTSVGXL YSGCRLTLLR XEKXXAATXV DXXCXXXXDP XXPGLDREXL YWELSXLTXX IXELGPYXLD RXSLYVNGFT 20101 263
HOTFAPNTST PGTSTVDLGT SGTPSSLPSP TSAGPLLVPF TLNFTITNLQ 20151 YEEDMHHPGS RKFNTTERVL QGILGPMFKN TSVGLLYSGC RLTLLEPEKN 20201 20251 GAATRVDAVC THRPDPKSPG LDREXLYWEL SXLTXXIXEL GPYXLDRXSL YVNGFXXXX XXXTSTEGTS XVXLXTSGTP XXXPXXTAPV PLLIPFTLNF 20301 TITNLHYEEN MOHPGSRKFN TTERVLOGIL RPLFKSTSVG PLYSGCRLTL 20351 Z42
LEPEKHGAAT GVDAICTLRL DPTGPGLDRE RLYWELSQLT NSVTELGPYT 20401 LDRDSLYVNG FTORSSVPTT SIPGTSAVHL ETSGTPASLP GHTAPGPLLV 20451 PFTLNFTITN LOYEVDMRHP GSRKFNTTER VLQGULKPLF KSTSVGPLYS 20501 GCRLTLLRPE KRGAATGVDT ICTHRLDPLN PGLDREQLYW ELSKLTRGII

2000 292 20601 ELGPYLLDRG SLYVNGFTHR NFVPITSTPG TSTVHLGTSE TPSSLPRPTV PGPLLVPFTL NFTITNLOYE EAMRHPGSRK FNTTERVLOG LLRPLFKNTS 247 IGPLYSSCRL TLLEPEKDKA ATRVDAICTH HPDPQSPGLN REQLYWELSQ LTHGITELGP YTLDRDSLYV DOFTHWSPIP TTSTPGTSIV NLGTSGIPPS LPETTEXXPL LXPFTLNFTI TNLXYEEXMX XPGSRKFNTT ERVLQGILKP LFKSTSVGPL YSGCRLTLLR PEKDGVATRV DAICTHRPDP KIPGLDRQQL YWELSQLTHS ITELGPYTLD RDSLYVNGFT QRSSVPTTST PGTFTVQPET 294 SETPSSLPGP TATGPVLLPF TLNFTITNLO YEEDMHRPGS RKFNTTERVL OGILMPLEKN TSVSSLYSGC RLTLLRÞEKD GAATRVDAVC THRPDPKSPG LDRERLYWKL SQLTHGITEL GPYTLDRHSL YVNGFTHQSS MTTTRTPDTS 784 TMHLATSRTP ASLSGPTFAS PLLVLFTINF TITNLRYEEN MHHPGSRKFN TTERVLOGIL RPVFKNTSVG PLYSGCRLTL LEPKKDGAAT KVDAICTYRP DPKSPGLDRE QLYWELSQLT HSITELGPYT QDRDSLYNVG FTQRSSVPTT 21201 5 VPGTPTVDL GTSGTPVSKP GPSAASPLLV LFTLNGTITN LRYEENMOHP GSRKFNTTER VLOGILRSLF KSTSVGPLYS GCRLTLLRPE KDGTATGVDA ICTHHPDPKS PRIDREOLYW ELSQLTHNIT ELGHYALDND SLFVNC THR 2.55 SSVSTTSTPG TPTVYLGASK TPASIFGPSA ASHLLILFTL NFTITNLRYE ENMWPGSRKF NTTERVLOGL LRPLFKNTSV GPLYSGSRLT LLRPEKDGEA TGVDAICTHR PDPTGPGLDR EQLYLELSQL THSITELGPY TLDRDSLYVN GETHRSSVPT TSIGVVSEEP FTLNFTINNL RYMADMGQPG SLKFNITDNV MKHILSPLFO RSSLGARYTG CRVIALESVK NGAETRVDLL CTYLOPLSGP GLPIKOVFHE LSQOTHGITR LGPYSLDKDS LYLNGVNEPG LDEPPTTPKP 297 ATTFLPPLSE ATTAMGYHLK TLTLNFTISN LQYSPDMGKG SATFNSTEGV LOHLIRPLEQ KSSMGPFYLG CQLISLRPEK DGAATGVDTT CTYHPDPVGP GLDIQQLYWE LSQLTHGVTQ LGFYVLDRDS LFINGYAPQN LSIRGEYDIN 798 FHIVNWNLSN PDPTSSEY